Syneron dismisses U.S. patent infringement suit against Eclipse Aesthetics, EndyMed

NewsGuard 100/100 Score
Feb 22 2013

Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company announced today, jointly with EndyMed Medical Ltd. and Eclipse Aesthetics, that Syneron has dismissed its United States patent infringement lawsuit against EndyMed and Eclipse Aesthetics relating to EndyMed's Fractional Skin Resurfacing Products. EndyMed and its United States distributor, Eclipse Aesthetics, agreed to immediately stop selling EndyMed's Fractional Skin Resurfacing Products in the United States but may continue to service and support previously purchased products and supply replacement electrodes for them.

Source:

Syneron Medical Ltd.

Posted in: Device / Technology News | Medical Patent News

Tags: , , ,

Comments (0)

Suggested Reading

Study reveals skin bacteria removal boosts brain attention signals
Reversing time: Hyaluronic acid injections offer lasting improvement in aging skin
Women's skin study shows distinct chemical changes in response to psychological stress
Do you wear makeup while you exercise? New research reveals the effects on skin and pores
Does IBD affect cancer risk?
Childhood obesity not linked to adult skin cancer risk, study says
Towards better diagnosis of neurodegenerative disorders: Skin biopsy for α-synuclein detection proves effective
Wound warriors: How microbes influence healing and infection risks

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study finds gut health key to combating skin diseases, eyes probiotics as potential treatment